Literature DB >> 20705106

Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Meital Gal-Tanamy1, Romy Zemel, Larissa Bachmatov, Rohit K Jangra, Assaf Shapira, Rodrigo A Villanueva, Minkyung Yi, Stanley M Lemon, Itai Benhar, Ran Tur-Kaspa.   

Abstract

Hepatitis C virus (HCV) infection is a common cause of chronic liver disease and a serious threat to human health. The HCV NS3/4A serine protease is necessary for viral replication and innate immune evasion, and represents a well-validated target for specific antiviral therapy. We previously reported the isolation of single-chain antibodies (scFvs) that inhibit NS3/4A protease activity in vitro. Expressed intracellularly (intrabodies), these scFvs blocked NS3-mediated proliferation of NS3-transfected cells. Here we show that anti-NS3 scFvs suppress HCV RNA replication when expressed intracellularly in Huh7 hepatoma cells bearing either subgenomic or genome-length HCV RNA replicons. The expression of intrabodies directed against NS3 inhibited the autonomous amplification of HCV replicons resistant to small-molecule inhibitors of the NS3/4A protease, and replicons derived from different HCV genotypes. The combination of intrabodies and interferon-α had an additive inhibitory effect on RNA replication in the replicon model. Intrabody expression also inhibited production of infectious HCV in a cell culture system. The NS3 protease activity was inhibited by the intrabodies in NS3-expressing cells. In contrast, cell-free synthesis of HCV RNA by preformed replicase complexes was not inhibited by intrabodies, suggesting that the major mode of inhibition of viral replication is inhibition of NS3/4A protease activity and subsequent suppression of viral polyprotein processing.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705106      PMCID: PMC4418563          DOI: 10.1016/j.antiviral.2010.08.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  46 in total

Review 1.  Intrabodies as antiviral agents.

Authors:  W A Marasco
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Authors:  Chao Lin; Cynthia A Gates; B Govinda Rao; Debra L Brennan; John R Fulghum; Yu-Ping Luong; J Daniel Frantz; Kai Lin; Sue Ma; Yun-Yi Wei; Robert B Perni; Ann D Kwong
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

3.  Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Authors:  Hongmei Mo; Liangjun Lu; Tami Pilot-Matias; Ron Pithawalla; Rubina Mondal; Sherie Masse; Tatyana Dekhtyar; Teresa Ng; Gennadiy Koev; Vincent Stoll; Kent D Stewart; John Pratt; Pam Donner; Todd Rockway; Clarence Maring; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

Authors:  Chiaki Okuse; Jo Ann Rinaudo; Kristine Farrar; Frances Wells; Brent E Korba
Journal:  Antiviral Res       Date:  2005-01       Impact factor: 5.970

Review 5.  Intrabodies: turning the humoral immune system outside in for intracellular immunization.

Authors:  W A Marasco
Journal:  Gene Ther       Date:  1997-01       Impact factor: 5.250

6.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody.

Authors:  R R Beerli; W Wels; N E Hynes
Journal:  Biochem Biophys Res Commun       Date:  1994-10-28       Impact factor: 3.575

8.  A novel high throughput screening assay for HCV NS3 serine protease inhibitors.

Authors:  Yevgeny Berdichevsky; Romy Zemel; Larisa Bachmatov; Alex Abramovich; Ruth Koren; Peramachi Sathiyamoorthy; Avi Golan-Goldhirsh; Ran Tur-Kaspa; Itai Benhar
Journal:  J Virol Methods       Date:  2003-02       Impact factor: 2.014

Review 9.  Recombinant single-chain immunotoxins against T and B cell leukemias.

Authors:  R J Kreitman; I Pastan
Journal:  Leuk Lymphoma       Date:  1994-03

10.  HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis.

Authors:  Vincenzo Summa; Alessia Petrocchi; Victor G Matassa; Marina Taliani; Ralph Laufer; Raffaele De Francesco; Sergio Altamura; Paola Pace
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

View more
  6 in total

1.  Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions.

Authors:  Shira Perez; Michael Gevor; Ateret Davidovich; Antony Kaspi; Katreena Yamin; Tom Domovich; Tomer Meirson; Avi Matityahu; Yehuda Brody; Salomon M Stemmer; Assam El-Osta; Izhak Haviv; Itay Onn; Meital Gal-Tanamy
Journal:  Nucleic Acids Res       Date:  2019-03-18       Impact factor: 16.971

2.  Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin.

Authors:  Assaf Shapira; Shiran Shapira; Meital Gal-Tanamy; Romy Zemel; Ran Tur-Kaspa; Itai Benhar
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

Review 3.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

4.  Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

Authors:  Shira Perez; Antony Kaspi; Tom Domovitz; Ateret Davidovich; Anat Lavi-Itzkovitz; Tomer Meirson; Jacinta Alison Holmes; Chia-Yen Dai; Chung-Feng Huang; Raymond T Chung; Assy Nimer; Assam El-Osta; Gur Yaari; Salomon M Stemmer; Ming-Lung Yu; Izhak Haviv; Meital Gal-Tanamy
Journal:  PLoS Genet       Date:  2019-06-19       Impact factor: 5.917

5.  Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation.

Authors:  Liat Ninio; Abraham Nissani; Tomer Meirson; Tom Domovitz; Alessandro Genna; Shams Twafra; Kolluru D Srikanth; Roba Dabour; Erez Avraham; Ateret Davidovich; Hava Gil-Henn; Meital Gal-Tanamy
Journal:  Cells       Date:  2019-11-05       Impact factor: 6.600

Review 6.  Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del.

Authors:  Frederik E Deiman; Nils Bomer; Peter van der Meer; Niels Grote Beverborg
Journal:  Curr Heart Fail Rep       Date:  2022-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.